Literature DB >> 11377679

Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

H P Horny1, P Valent.   

Abstract

An increase in mast cell (MC) numbers in hemopoietic tissues may be associated with (a) primary neoplastic MC disease (mastocytosis); (b) non-mast cell lineage myelogenous disorders (myelodysplastic or myeloproliferative syndromes and myeloid leukemias); or (c) reactive, i.e. non-clonal states (MC hyperplasia and reactive mastocytosis). However, the histologic discrimination between hyperplastic states and neoplastic MC proliferative disorders is sometimes very difficult. MC hyperplasia is characterized by a diffuse increase in mature, round or spindle-shaped, metachromatic MC that are loosely scattered throughout the tissue and do not form dense focal infiltrates, even in states of marked hyperplasia. However, loosely scattered MC are also a prominent feature of many cases of myelodysplastic syndromes and acute leukemia involving the MC lineage. In contrast, the demonstration of dense, focal and/or diffuse MC infiltrates can be regarded as indicative of primary MC disease/mastocytosis. In addition to the highly diagnostic focal MC infiltrates, mastocytosis may also present with a predominantly diffuse or a mixed (diffuse and focal) infiltration pattern. The relatively rare diffuse pattern is usually dominated by atypical, often hypogranulated or even non-metachromatic MC and is associated with the aggressive or frankly malignant subtypes of systemic mastocytosis and MC leukemia. Although the demonstration of MC infiltrates in Giemsa-stained tissue sections is still very important for the diagnosis of mastocytosis, immunohistochemical techniques using antibodies against MC-associated antigens such as tryptase or c-kit (CD117) are essential for the identification of highly atypical, hypogranulated MC, especially in MC leukemia, and for the detection of small and even minute MC infiltrates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377679     DOI: 10.1016/s0145-2126(01)00021-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  45 in total

1.  Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.

Authors:  T Gülen; B Sander; G Nilsson; J Palmblad; K Sotlar; H-P Horny; H Hägglund
Journal:  Med Oncol       Date:  2012-06-03       Impact factor: 3.064

2.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

3.  Advanced mast cell disease: an Italian Hematological Multicenter experience.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Morena Caira; Michela Rondoni; Maria Teresa Van Lint; Anna Candoni; Bernardino Allione; Chiara Cattaneo; Laura Marbello; Cecilia Caramatti; Enrico Maria Pogliani; Emilio Iannitto; Fiorina Giona; Felicetto Ferrara; Rosangela Invernizzi; Rosa Fanci; Monia Lunghi; Luana Fianchi; Grazia Sanpaolo; Pietro Maria Stefani; Alessandro Pulsoni; Giovanni Martinelli; Giuseppe Leone; Pellegrino Musto
Journal:  Int J Hematol       Date:  2008-11-26       Impact factor: 2.490

4.  Systemic mastocytosis: predominantly involving the bone, a case report.

Authors:  Ketan P Mallya; Sushma Belurkar; Annamma Kurian; Laxmi Rao; Bikash Singhania
Journal:  J Clin Diagn Res       Date:  2013-10-05

5.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Authors:  Barbara Peter; Karoline V Gleixner; Sabine Cerny-Reiterer; Harald Herrmann; Viviane Winter; Emir Hadzijusufovic; Veronika Ferenc; Karina Schuch; Irina Mirkina; Hans-Peter Horny; Winfried F Pickl; Leonhard Müllauer; Michael Willmann; Peter Valent
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

6.  Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Authors:  Gregor Hoermann; Sabine Cerny-Reiterer; Andrea Perné; Miriam Klauser; Konrad Hoetzenecker; Katharina Klein; Leonhard Müllauer; Marion Gröger; Sebastian M B Nijman; Walter Klepetko; Peter Valent; Matthias Mayerhofer
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

7.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 8.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

9.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Authors:  Georg Greiner; Nadine Witzeneder; Angelika Berger; Klaus Schmetterer; Gregor Eisenwort; Ana-Iris Schiefer; Simone Roos; Theresia Popow-Kraupp; Leonhard Müllauer; Johannes Zuber; Veronika Sexl; Lukas Kenner; Wolfgang R Sperr; Peter Valent; Matthias Mayerhofer; Gregor Hoermann
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

10.  An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).

Authors:  H-P Horny; K Sotlar; F Stellmacher; P Valent; J Grabbe
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.